Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
The company buys in a PI3Kα and mTOR combo.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.